Zusammenfassung
Klassifikation
Das Schädel-Hirn-Trauma (SHT) wird entsprechend der neurologischen Beeinträchtigung und dem damit verbundenen Punktwert im Glasgow-Coma-Score (GCS) eingeteilt in leicht (GCS: 13 bis 15 Punkte), mittel (GCS: 9 bis 12 Punkte) und schwer (GCS: 3 bis 8 Punkte).
Diagnostik
Während das diagnostische Management beim mittleren und schweren SHT immer die kraniale Computertomographie (CCT) beinhaltet, stellt das leichte SHT ein diagnostisches Dilemma dar. Die Ursache hierfür ist darin begründet, dass die neurologischen Beeinträchtigungen weitaus häufiger durch Begleitintoxikationen usw. bedingt sind als durch intrakraniale Pathologien, dies jedoch nicht als Ausschlusskriterium herangezogen werden kann, sodass derzeit alle Patienten mit SHT mittels CCT untersucht werden müssen. Serummarker wurden als zusätzliches diagnostisches Werkzeug propagiert, um die Indikationsstellung zur CCT verbessern zu können.
Literaturdaten
Die derzeitige Studienlage zu Serummarkern in der Diagnostik des leichten SHT wird zusammengefasst, und der derzeitige Wissensstand wird anhand einer übersichtlichen Grafik klar dargestellt.
Abstract
Classification
In patients with traumatic brain injury (TBI), the Glasgow Coma Scale (GCS) is the most commonly used system for classification of TBI severity. Using the GCS score TBI can be classified into mild (GCS 15-13), moderate (GCS 13-9) and severe (GCS 8-3).
Diagnostics
In patients with moderate or severe TBI cranial computed tomography (CCT) is obligatory. In patients presenting with mild TBI physicians face a dilemma because the neurological impairment occurs more often as a corollary of acute intoxication or pre-existing conditions and not due to intracranial lesions. Nevertheless, to exclude the risk of intracranial bleeding all patients with mild TBI have to undergo neuroradiological imaging. Individuals suffering from mild TBI would therefore benefit from additional evaluation of serum parameters that help to determine the necessity for a CCT scan.
Literature
This review provides a critical assessment of current serum parameters used for the diagnosis of mild TBI and the current state of knowledge.
Literatur
Balakathiresan N, Bhomia M, Chandran R et al (2012) MicroRNA let-7i is a promising serum biomarker for blast-induced traumatic brain injury. J Neurotrauma 29(7):1379–1387
Bazarian JJ, Zemlan FP, Mookerjee S, Stigbrand T (2006) Serum S-100B and cleaved-tau are poor predictors of long-term outcome after mild traumatic brain injury. Brain Inj 20:759–765
Bazarian JJ, Zhong J, Blyth B et al (2007) Diffusion tensor imaging detects clinically important axonal damage after mild traumatic brain injury: a pilot study. J Neurotrauma 24:1447–1459
Begaz T, Kyriacou DN, Segal J, Bazarian JJ (2006) Serum biochemical markers for post-concussion syndrome in patients with mild traumatic brain injury. J Neurotrauma 23:1201–1210
Berger RP, Bazaco MC, Wagner AK et al (2010) Trajectory analysis of serum biomarker concentrations facilitates outcome prediction after pediatric traumatic and hypoxemic brain injury. Dev Neurosci 32:396–405
Berger RP, Hayes RL, Richichi R et al (2012) Serum concentrations of ubiquitin C-terminal hydrolase-L1 and αII-spectrin breakdown product 145 kDa correlate with outcome after pediatric TBI. J Neurotrauma 29(1):162–167
Biberthaler P, Mussack T, Kanz KG et al (2004) Identifikation von Hochrisikopatienten nach leichtem Schädel-Hirn-Trauma. Messung des neuroglialen Proteins S100. Unfallchirurg 107(3):197–202
Biberthaler P, Linsenmeier U, Pfeifer K et al (2006) Serum S-100B concentration provides additional information for the indication of computed tomography in patients after minor head injury: a prospective multicenter study. Shock 25(5):446–453
Blyth BJ, Farahvar A, He H et al (2011) Elevated serum ubiquitin carboxy-terminal hydrolase L1 is associated with abnormal bloodbrain barrier function after traumatic brain injury. J Neurotrauma 28:2453–2462
Büki A, Okonkwo DO, Wang KK, Povlishock JT (2000) Cytochrome C release and caspase activation in traumatic axonal injury. J Neurosci 20(8):2825–2834
Cassidy JD, Carroll LJ, Peloso PM et al (2004) Incidence, risk factors and prevention of mild traumatic brain injury: results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. J Rehabil Med Suppl 43:28–60
Dash P, Zhao J, Hergenroeder G (2010) Biomarkers for the diagnosis, prognosis, and evaluation of treatment efficacy for traumatic brain injury. Neurotherapeutics 7(1):100–114
DeKosky ST, Abrahamson EE, Ciallella JR et al (2007) Association of increased cortical soluble Aβ42 levels with diffuse plaques after severe brain injury in humans. Arch Neurol 64:541–544
d’Hemecourt P (2011) Subacute symptoms of sports-related concussion: outpatient management and return to play. Clin Sports Med 30:63–72, viii
Diener HC, Putzki N, Berlitt C et al (2008) Leitlinien für Diagnostik und Therapie in der Neurologie, 4. überarb. Aufl. Thieme, Stuttgart New York, S 654
Donato R (2003) Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 60(6):540–551
Evans RW (1992) The postconcussion syndrome and the sequelae of mild head injury. Neurol Clin 10(4):815–847
Fenelon K, Mukai J, Xu B et al (2011) Deficiency of Dgcr8, a gene disrupted by the 22q11.2 microdeletion, results in altered short-term plasticity in the prefrontal cortex. Proc Natl Acad Sci USA 108:4447–4452
Hall RC, Hall RC, Chapman MJ (2005) Definition, diagnosis, and forensic implications of postconcussional syndrome. Psychosomatics 46(3):195–202
Healy DG, Abou-Sleiman PM, Wood NW (2005) Genetic causes of Parkinson’s disease: UCHL-1. Cell Tissue Res 318(1):189–194
Hoge CW, Castro CA, Messer SC et al (2004) Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med 351:13–22
Honda M, Tsuruta R, Kaneko T et al (2010) Serum glial fibrillary acidic protein is a highly specific biomarker for traumatic brain injury in humans compared with S-100B and neuron-specific enolase. J Trauma 69:104–109
Huh GY, Glantz SB, Je S et al (2001) Calpain proteolysis of alpha-II-spectrin in the normal adult human brain. Neurosci Lett 316(1):41–44
Hulsebosch CE (2008) Gliopathy ensures persistent inflammation and chronic pain after spinal cord injury. Exp Neurol 214:6–9
Ikonomovic MD et al (2004) Alzheimer’s pathology in human temporal cortex surgically excised after severe brain injury. Exp Neurol 190:192–203
Ingebrigtsen T, Romner B (2003) Biochemical serum markers for brain damage: a short review with emphasis on clinical utility in mild head injury. Restor Neurol Neurosci 21:171–176
Isaacs A, Baker M, Wavrant-De Vrièze F, Hutton M (1998) Determination of the gene structure of human GFAP and absence of coding region mutations associated with frontotemporal dementia with parkinsonism linked to chromosome 17. Genomics 51(1):152–154
Iverson GL (2005) Outcome from mild traumatic brain injury. Curr Opin Psychiatry 18(3):301–317
Jacobson RR (1995) The post-concussional syndrome: physiogenesis, psychogenesis and malingering. An integrative model. J Psychosom Res 39(6):675–693
Jagoda AS, Bazarian JJ, Bruns JJ Jr et al (2008) Clinical policy: neuroimaging and decision making in adult mild traumatic brain injury in the acute setting. Ann Emerg Med 52:714–748
Jeter CB, Hergenroeder GW, Hylin MJ et al (2012) Biomarkers for the diagnosis and prognosis of mild traumatic brain injury/concussion. J Neurotrauma Oct 12. [Epub ahead of print]
Kövesdi E, Lückl J, Bukovics P et al (2010) Update on protein biomarkers in traumatic brain injury with emphasis on clinical use in adults and pediatrics. Acta Neurochir 152(1):1–17
Kosaka N, Iguchi H, Yoshioka Y et al (2010) Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 285:17.442–17.452
Langlois JA, Rutland-Brown W, Wald MM (2006) The epidemiology and impact of traumatic brain injury: a brief overview. J Head Trauma Rehabil 21:375–378
Li J, Li XY, Fenf DF, Pan DC (2010) Biomarkers associated with diffuse traumatic axonal injury: exploring pathogenesis, early diagnosis, and prognosis. J Trauma 69(6):1610–1618
Lima DP, Sima FC, Abib SC, Figueiredo LF de (2008) Quality of life and neuropsychological changes in mild head trauma. Late analysis and correlation with S100B protein and cranial CT scan performed at hospital admission. Injury 39:604–611
Ling KH, Brautigan PJ, Hahn CN et al (2011) Deep sequencing analysis of the developing mouse brain reveals a novel microRNA. BMC Genomics 12:176
Ma M, Lindsell CJ, Rosenberry CM et al (2008) Serum cleaved tau does not predict postconcussion syndrome after mild traumatic brain injury. Am J Emerg Med 26:763–776
Madathil SK, Nelson PT, Saatman KE, Wilfred BR (2011) MicroRNAs in CNS injury: potential roles and therapeutic implications. Bioessays 33(1):21–26
Magnoni S, Esparza TJ, Conte V et al (2012) Tau elevations in the brain extracellular space correlate with reduced amyloid-β levels and predict adverse clinical outcomes after severe traumatic brain injury. Brain 135(4):1268–1280
Mittenberg W, Strauman S (2000) Diagnosis of mild head injury and the postconcussion syndrome. J Head Trauma Rehabil 15(2):783–791
Möllmann FT (2006) Epidemiologie, Unfallursachen und akutklinische Initialversorgung beim Schädel-Hirn-Trauma: Eine regionale multizentrische prospektive Studie zur Versorgung Schädel-Hirn traumatisierter Patienten in der Bundesrepublik Deutschland. Med. Dissertation, Westfälische Wilhelms-Universität Münster
Mondello S, Linnet A, Buki A et al (2012) Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury. Neurosurgery 70(3):666–675
Mondello S, Jeromin A, Buki A et al (2012) Glial neuronal ratio: a novel index for differentiating injury type in patients with severe traumatic brain injury. J Neurotrauma 29(6):1096–1104
Mott TF, McConnon ML, Rieger BP (2012) Subacute to chronic mild traumatic brain injury. Am Fam Physician 86(11):1045–1051
Nygaard O, Langbakk B, Romner B (1998) Neuron-specific enolase concentrations in serum and cerebrospinal fluid in patients with no previous history of neurological disorder. Scand J Clin Lab Invest 58:183–186
Nygren De BC, Fredman P, Lundin A et al (2004) S100 in mild traumatic brain injury. Brain Inj 18:671–683
Oliva D, Calì L, Feo S, Giallongo A (1991) Complete structure of the human gene encoding neuron-specific enolase. Genomics 10(1):157–165
Olver J (2005) Traumatic brain injury – the need for support and follow up. Aust Fam Physician 34(4):269–271
Otto M, Holthusen S, Bahn E et al (2000) Boxing and running lead to a rise in serum levels of S-100B protein. Int J Sports Med 21:551–555
Papa L, Akinyi L, Liu MC et al (2010) Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit Care Med 38:138–144
Papa L, Lewis LM, Falk JL et al (2011) Elevated levels of serum glial fibrillary acidic protein breakdown products in mild and moderate traumatic brain injury are associated with intracranial lesions and neurosurgical intervention. Ann Emerg Med 59(6):471–483
Pardes Berger R, Adelson PD, Richichi R, Kochanek PM (2006) Serum biomarkers after traumatic and hypoxemic brain injuries: insight into the biochemical response of the pediatric brain to inflicted brain injury. Dev Neurosci 28:327–335
Pelinka LE, Kroepfl A, Schmidhammer R et al (2004) Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. J Trauma 57:1006–1012
Redell JB, Liu Y, Dash PK (2009) Traumatic brain injury alters expression of hippocampal microRNAs: potential regulators of multiple pathophysiological processes. J Neurosci Res 87:1435–1448
Redell JB, Moore AN, Ward NH III et al (2010) Human traumatic brain injury alters plasma microRNA levels. J Neurotrauma 27:2147–2156
Ross SA, Cunningham RT, Johnston CF, Rowlands BJ (1996) Neuron-specific enolase as an aid to outcome prediction in head injury. Br J Neurosurg 10:471–476
Ryan LM, Warden DL (2003) Post concussion syndrome. Int Rev Psychiatry 15(4):310–316
Saatman KE, Duhaime AC, Bullock R et al (2008) Classification of traumatic brain injury for targeted therapies. J Neurotrauma 25:719–738
Schmechel D, Marangos PJ, Brightman M (1978) Neuron-specific enolase is a molecular marker for peripheral and central neuroendocrine cells. Nature 276:834–836
Schöler N, Langer C, Dohner H et al (2010) Serum microRNAs as a novel class of biomarkers: a comprehensive review of the literature. Exp Hematol 38:1126–1130
Simpson RJ, Lim JW, Moritz RL, Mathivanan S (2009) Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics 6:267–283
Stalnacke BM, Bjornstig U, Karlsson K, Sojka P (2005) One-year follow-up of mild traumatic brain injury: post-concussion symptoms, disabilities and life satisfaction in relation to serum levels of S-100B and neurone-specific enolase in acute phase. J Rehabil Med 37:300–305
Topolovec-Vranic J, Pollmann-Mudryj MA, Ouchterlony D et al (2011) The value of serum biomarkers in prediction models of outcome after mild traumatic brain injury. J Trauma 71:478–486
Uchino Y, Okimura Y, Tanaka M et al (2001) Computed tomography and magnetic resonance imaging of mild head injury – is it appropriate to classify patients with Glasgow Coma Scale score of 13–15 as „mild injury“? Acta Neurochir (Wien) 143:1031–1037
Unden J, Romner B (2009) A new objective method for CT triage after minor head injury – serum S100B. Scand J Clin Lab Invest 69:13–17
Verma N, Karmakar M, Singh KP, Smita S (2013) Structural and dynamic insights into S100B protein activity inhibition by melittin for the treatment of epilepsy. Int J Comp App NSAAILS 1:55–60
Vos PE, Lamers KJ, Hendriks JC et al (2004) Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology 62:1303–1310
Vos PE, Jacobs B, Andriessen TM et al (2010) GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology 75:1786–1793
Williams DH, Levin HS, Eisenberg HM (1990) Mild head injury classification. Neurosurgery 27:422–428
Woertgen C, Rothoerl RD, Holzschuh M et al (1997) Comparison of serial S-100 and NSE serum measurements after severe head injury. Acta Neurochir (Wien) 139:1161–1164
Zimmer DB, Cornwall EH, Landar A, Song W (1995) The S100 protein family: history, function, and expression. Brain Res Bull 37:417–429
Interessenkonflikt
Der korrespondierende Autor gibt für sich und seinen Koautor an, dass kein Interessenkonflikt besteht.
The supplement containing this article is not sponsored by industry.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wanke-Jellinek, L., Biberthaler, P. Serummarker nach Schädel-Hirn Trauma. Trauma Berufskrankh 15 (Suppl 2), 107–114 (2013). https://doi.org/10.1007/s10039-013-1957-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10039-013-1957-2